CClinicalTrials.gg
CompletedNCT03459352Updated Aug 26, 2020

Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients

An interventional study of ePRO in Cancer, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Duke University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A pilot study of an ePRO system in cancer patients receiving systemic therapies.

Read the detailed description

The primary purpose of this pilot study is to determine the feasibility of the Noona Healthcare Mobile PRO Application to describe oncology patient engagement using a web-based symptom self-monitoring instrument. Additionally, the studyy will dentify side effects as well as long term or chronic adverse events during and following cancer therapy based on the United States (US) National Cancer Institute (NCI) Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE), and identify patients to participate in future long-term Quality of Life studies following cancer therapy.

The study is not intended to compare outcomes between groups receiving different therapies.

02

Conditions studied

  • Cancer

Keywords

  • Cancer
  • Patient Reported Outcomes
  • Symptom management
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Individuals (men and women) aged 18 years or older
  2. History cancer with no limitation on prior lines of therapy in the metastatic setting
  3. ECOG performance status of 0-2
  4. Estimated life expectancy of at least 12 months
  5. Access to smartphone, tablet or computer with capability to utilize symptom-tracking application
  6. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
  7. Willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Concurrent disease or condition that interferes with participation or safety
  2. Non-English speaking, as the application is developed in the English language
  3. Children will not be included in the study. The pattern of disease and symptoms are different in children than in an adult population. The web-based tool was designed based on the symptom experience of adults with cancer.
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    ePRO

    There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.

    Other: ePRO

Interventions

  • OtherePRO

    Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms. These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit. Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction.

    Also known as: Noona web-based platform

05

What researchers measure

Primary outcomes

  1. Subject participation

    total number of subjects that participate in the use of a web-based system

    Time frame: 12 months

06

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
07

Registry details

Key details

Study ID
NCT03459352
Lead sponsor
Duke University
Collaborators
Noona Healthcare Inc
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Jun 18, 2018
Primary completion
Apr 4, 2020
Completion
Apr 4, 2020
Last update
Aug 26, 2020

Study contacts

H. Kim Lyerly, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion